Free Trial

Best Stocks Under $5 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $5.00 (5 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Birchcliff Energy stock logo

1. Birchcliff Energy OTCMKTS:BIREF

$4.33 -0.02 (-0.36%)
As of 09/17/2025 02:52 PM Eastern

Birchcliff Energy Ltd., an intermediate oil and natural gas company, explores for, develops, and produces natural gas, light oil, condensate, and other natural gas liquids in Western Canada. More about Birchcliff Energy

Market Capitalization
$1.18 billion
P/E Ratio
22.81
Consensus Rating
Strong Buy
Volume
3,033 shares
Average Volume
48,384 shares
Today's Range
$4.32
$4.40
Senseonics stock logo

2. Senseonics NYSE:SENS

$0.45 +0.00 (+0.78%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More about Senseonics

Market Capitalization
$366.61 million
P/E Ratio
-3.46
Consensus Rating
Buy
Consensus Price Target
$1.54 (+240.9% Upside)
Volume
515,736 shares
Average Volume
7.88 million shares
Ultrapar Participacoes stock logo

3. Ultrapar Participacoes NYSE:UGP

$3.98 +0.04 (+0.89%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ultrapar Participações SA, through its subsidiaries, operates in the energy and infrastructure business in Brazil. The company distributes liquefied petroleum gas to residential, commercial, and industrial consumers, in addition to renewable electricity and compressed natural gas. More about Ultrapar Participacoes

Market Capitalization
$4.43 billion
P/E Ratio
8.83
Consensus Rating
Buy
Consensus Price Target
$3.20 (-19.7% Downside)
Volume
15,995 shares
Average Volume
1.83 million shares
TuHURA Biosciences stock logo

4. TuHURA Biosciences NASDAQ:HURA

$2.50 +0.08 (+3.09%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. More about TuHURA Biosciences

Market Capitalization
$125.13 million
Consensus Rating
Buy
Consensus Price Target
$12.67 (+405.7% Upside)
Volume
5,766 shares
Average Volume
299,709 shares
Today's Range
$2.45
$2.49
Climb Bio stock logo

5. Climb Bio NASDAQ:CLYM

$2.12 0.00 (0.00%)
As of 09:34 AM Eastern

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. More about Climb Bio

Market Capitalization
$143.65 million
P/E Ratio
-3.03
Consensus Rating
Buy
Consensus Price Target
$9.00 (+324.5% Upside)
Volume
26,682 shares
Average Volume
360,797 shares
Western Copper & Gold stock logo

6. Western Copper & Gold NYSE:WRN

$1.62 -0.04 (-2.34%)
As of 09:34 AM Eastern

Western Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & Gold

Market Capitalization
$326.91 million
P/E Ratio
-81.06
Consensus Rating
Buy
Consensus Price Target
$4.00 (+146.7% Upside)
Volume
16,552 shares
Average Volume
387,919 shares
TriSalus Life Sciences stock logo

7. TriSalus Life Sciences NASDAQ:TLSI

$4.79 -0.01 (-0.13%)
As of 09:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. More about TriSalus Life Sciences

Market Capitalization
$237.37 million
P/E Ratio
-4.03
Consensus Rating
Buy
Consensus Price Target
$10.90 (+127.4% Upside)
Volume
812 shares
Average Volume
67,123 shares
Hochschild Mining stock logo

8. Hochschild Mining OTCMKTS:HCHDF

$4.30 -0.09 (-1.98%)
As of 09/17/2025 03:57 PM Eastern

Hochschild Mining plc, a precious metals company, engages in the exploration, mining, processing, and sale of gold and silver in the Americas. More about Hochschild Mining

Market Capitalization
$2.21 billion
Consensus Rating
Buy
Volume
10,185 shares
Average Volume
40,761 shares
Today's Range
$4.24
$4.39
50-Day Range
$3.56
$4.70
FiscalNote stock logo

9. FiscalNote NYSE:NOTE

$4.62 +0.23 (+5.11%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FiscalNote Holdings, Inc operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. More about FiscalNote

Market Capitalization
$66.25 million
P/E Ratio
-1.20
Consensus Rating
Buy
Consensus Price Target
$29.25 (+532.4% Upside)
Volume
7,811 shares
Average Volume
248,581 shares
Medicus Pharma stock logo

10. Medicus Pharma NASDAQ:MDCX

$2.49 +0.08 (+3.32%)
As of 09:34 AM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. More about Medicus Pharma

Market Capitalization
$44.37 million
P/E Ratio
-1.86
Consensus Rating
Buy
Consensus Price Target
$23.50 (+843.8% Upside)
Volume
47,827 shares
Average Volume
237,082 shares
zSpace stock logo

11. zSpace NASDAQ:ZSPC

$1.68 0.00 (0.00%)
As of 09:31 AM Eastern

zSpace Technologies, Inc is a provider of commercial augmented reality and virtual reality technology principally in the education market. More about zSpace

Market Capitalization
$40.39 million
Consensus Rating
Buy
Consensus Price Target
$10.00 (+495.2% Upside)
Volume
5,366 shares
Average Volume
75,098 shares
Today's Range
$1.66
$1.71
Plus Therapeutics stock logo

12. Plus Therapeutics NASDAQ:PSTV

$0.44 +0.02 (+4.42%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More about Plus Therapeutics

Market Capitalization
$42.88 million
P/E Ratio
-0.19
Consensus Rating
Buy
Consensus Price Target
$7.88 (+1,710.3% Upside)
Volume
2.26 million shares
Average Volume
18.03 million shares
Mereo BioPharma Group stock logo

13. Mereo BioPharma Group NASDAQ:MREO

$1.77 +0.04 (+2.20%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma Group

Market Capitalization
$279.05 million
P/E Ratio
-25.07
Consensus Rating
Buy
Consensus Price Target
$7.40 (+318.6% Upside)
Volume
48,964 shares
Average Volume
1.65 million shares
CytomX Therapeutics stock logo

14. CytomX Therapeutics NASDAQ:CTMX

$2.00 +0.07 (+3.37%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More about CytomX Therapeutics

Market Capitalization
$327.35 million
P/E Ratio
3.54
Consensus Rating
Buy
Consensus Price Target
$5.30 (+165.7% Upside)
Volume
171,700 shares
Average Volume
3.19 million shares
ImmunityBio stock logo

15. ImmunityBio NASDAQ:IBRX

$2.88 +0.12 (+4.17%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. More about ImmunityBio

Market Capitalization
$2.73 billion
P/E Ratio
-6.01
Consensus Rating
Buy
Consensus Price Target
$10.75 (+273.9% Upside)
Volume
982,302 shares
Average Volume
8.07 million shares
Stardust Power stock logo

16. Stardust Power NASDAQ:SDST

$2.89 -0.01 (-0.34%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.

Market Capitalization
$24.41 million
P/E Ratio
-0.52
Consensus Rating
Buy
Consensus Price Target
$51.13 (+1,669.0% Upside)
Volume
11,589 shares
Average Volume
406,970 shares
Ur Energy stock logo

17. Ur Energy NYSEAMERICAN:URG

$1.52 +0.03 (+1.68%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization
$549.07 million
P/E Ratio
-8.85
Consensus Rating
Buy
Consensus Price Target
$2.48 (+63.4% Upside)
Volume
523,418 shares
Average Volume
5.49 million shares
SAB Biotherapeutics stock logo

18. SAB Biotherapeutics NASDAQ:SABS

$2.70 +0.12 (+4.81%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. More about SAB Biotherapeutics

Market Capitalization
$28.06 million
P/E Ratio
-0.67
Consensus Rating
Buy
Consensus Price Target
$9.75 (+260.6% Upside)
Volume
72,336 shares
Average Volume
566,874 shares
Perspective Therapeutics stock logo

19. Perspective Therapeutics NYSE:CATX

$3.27 +0.23 (+7.43%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective Therapeutics

Market Capitalization
$242.10 million
Consensus Rating
Buy
Consensus Price Target
$12.56 (+284.4% Upside)
Volume
29,093 shares
Average Volume
916,202 shares
Today's Range
$3.09
$3.26
Quince Therapeutics stock logo

20. Quince Therapeutics NASDAQ:QNCX

$1.62 +0.01 (+0.62%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince Therapeutics

Market Capitalization
$87.55 million
P/E Ratio
-1.50
Consensus Rating
Buy
Consensus Price Target
$8.14 (+402.6% Upside)
Volume
329 shares
Average Volume
225,518 shares
Protara Therapeutics stock logo

21. Protara Therapeutics NASDAQ:TARA

$3.09 +0.06 (+1.95%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. More about Protara Therapeutics

Market Capitalization
$118.40 million
P/E Ratio
-1.89
Consensus Rating
Buy
Consensus Price Target
$19.60 (+534.5% Upside)
Volume
2,976 shares
Average Volume
308,018 shares
Biomea Fusion stock logo

22. Biomea Fusion NASDAQ:BMEA

$2.04 +0.08 (+4.23%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea Fusion

Market Capitalization
$121.34 million
P/E Ratio
-0.67
Consensus Rating
Buy
Consensus Price Target
$14.80 (+624.4% Upside)
Volume
92,205 shares
Average Volume
1.28 million shares
Ovid Therapeutics stock logo

23. Ovid Therapeutics NASDAQ:OVID

$1.16 +0.01 (+0.43%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization
$81.78 million
P/E Ratio
-2.17
Consensus Rating
Buy
Consensus Price Target
$3.10 (+166.1% Upside)
Volume
42,068 shares
Average Volume
1.03 million shares
Nuvation Bio stock logo

24. Nuvation Bio NYSE:NUVB

$3.41 +0.15 (+4.63%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. More about Nuvation Bio

Market Capitalization
$1.17 billion
P/E Ratio
-5.44
Consensus Rating
Buy
Consensus Price Target
$7.50 (+119.9% Upside)
Volume
149,076 shares
Average Volume
4.51 million shares
Foghorn Therapeutics stock logo

25. Foghorn Therapeutics NASDAQ:FHTX

$4.94 +0.15 (+3.02%)
As of 09:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. More about Foghorn Therapeutics

Market Capitalization
$276.43 million
P/E Ratio
-4.11
Consensus Rating
Buy
Consensus Price Target
$10.67 (+115.7% Upside)
Volume
7,334 shares
Average Volume
124,665 shares